Following an abbreviated submission
Methylphenidate prolonged-release capsule (Medikinet XL®) is accepted for restricted use within NHS Scotland as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children over 6 years of age when remedial measures alone prove insufficient.
Like other modified release methylphenidate formulations, it should be considered second line and used for patients requiring methylphenidate in the morning and afternoon when administration of a midday dose is problematic or inappropriate. Treatment should be under the supervision of a specialist in childhood behaviour disorders. The pharmacokinetic profile of Medikinet XL® differs from those of other modified release formulations of methylphenidate.
Download detailed advice26KB (PDF)
Medicine details
- Medicine name:
- methylphenidate HCI Prolonged release (Medikinet XL)
- SMC ID:
- 388/07
- Indication:
- attention deficit hyperactivity disorder (ADHD) in children over 6 years of age
- Pharmaceutical company
- UK Distributer Flynn Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 09 July 2007